Regulation of biotechnology in the United States and Canada

Abstract

The regulation of biotechnology in the United States and Canada is based on principles that reflect respect for the new technology, yet also recognize that most traditional approaches to regulation, employing sound science and common sense, still apply. Four specific principles form the framework on which regulatory schemes are based: (1) the products of biotechnology will not differ fundamentally from unmodified organisms or from conventional products; (2) the product rather than the process shall be regulated; (3) regulation should be based on the end use of the product and will be conducted on a case-by-case basis; and (4) the existing laws provide adequate authority for regulating the products of biotechnology. This report summarizes the regulatory approaches taken in various organisms and products. Special emphasis is given to: (1) issuance of entry permits for genetically-engineered plants and micro-organisms; (2) licensing of genetically-engineered veterinary biological products; and (3) permits for movement and release into the environment. A three-category classification system is described for dealing with hybridomas and recombinant-derived products, based on their biological characteristics and safety concerns. Categories range from relatively simple inactivated recombinant animal vaccines to products using live vectors to carry recombinant-derived foreign genes that code for immunizing antigens and/or other immune stimulants. This paper stresses that few fields of contemporary science and technology hold forth more possibilities and greater expectations than biotechnology. It is therefore of utmost importance that animal health officials and scientists ensure that the products of biotechnology will not cause or transmit infectious disease, adversely affect the environment or adulterate food products.